
ABVC Biopharma Inc
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $1.07
- Today's High:
- $1.18
- Open Price:
- $1.07
- 52W Low:
- $0.5
- 52W High:
- $3.13
- Prev. Close:
- $1.07
- Volume:
- 21548
Company Statistics
- Market Cap.:
- $21.53 million
- Book Value:
- 0.183
- Revenue TTM:
- $342996
- Operating Margin TTM:
- -5372.83%
- Gross Profit TTM:
- $350711
- Profit Margin:
- 0%
- Return on Assets TTM:
- -100.88%
- Return on Equity TTM:
- -281.76%
Company Profile
ABVC Biopharma Inc had its IPO on 2017-10-11 under the ticker symbol ABVC.
The company operates in the Healthcare sector and Biotechnology industry. ABVC Biopharma Inc has a staff strength of 28 employees.
Stock update
Shares of ABVC Biopharma Inc opened at $1.07 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.07 - $1.18, and closed at $1.13.
This is a +5.61% increase from the previous day's closing price.
A total volume of 21,548 shares were traded at the close of the day’s session.
In the last one week, shares of ABVC Biopharma Inc have slipped by -8.87%.
ABVC Biopharma Inc's Key Ratios
ABVC Biopharma Inc has a market cap of $21.53 million, indicating a price to book ratio of 4.08 and a price to sales ratio of 66.5973.
In the last 12-months ABVC Biopharma Inc’s revenue was $342996 with a gross profit of $350711 and an EBITDA of $-18407944. The EBITDA ratio measures ABVC Biopharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ABVC Biopharma Inc’s operating margin was -5372.83% while its return on assets stood at -100.88% with a return of equity of -281.76%.
In Q3, ABVC Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 57.3%.
ABVC Biopharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ABVC Biopharma Inc’s profitability.
ABVC Biopharma Inc stock is trading at a EV to sales ratio of 75.3857 and a EV to EBITDA ratio of -1.46. Its price to sales ratio in the trailing 12-months stood at 66.5973.
ABVC Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $10.48 million
- Total Liabilities
- $3.89 million
- Operating Cash Flow
- $-1523150.00
- Capital Expenditure
- $4357
- Dividend Payout Ratio
- 0%
ABVC Biopharma Inc ended 2025 with $10.48 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.48 million while shareholder equity stood at $5.92 million.
ABVC Biopharma Inc ended 2025 with $0 in deferred long-term liabilities, $3.89 million in other current liabilities, 32632.00 in common stock, $-50040501.00 in retained earnings and $0.00 in goodwill. Its cash balance stood at $1.32 million and cash and short-term investments were $1.40 million. The company’s total short-term debt was $2,230,002 while long-term debt stood at $0.
ABVC Biopharma Inc’s total current assets stands at $2.90 million while long-term investments were $816160.00 and short-term investments were $77583.00. Its net receivables were $547680.00 compared to accounts payable of $0 and inventory worth $20489.00.
In 2025, ABVC Biopharma Inc's operating cash flow was $-1523150.00 while its capital expenditure stood at $4357.
Comparatively, ABVC Biopharma Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $1.13
- 52-Week High
- $3.13
- 52-Week Low
- $0.5
- Analyst Target Price
- $2.02
ABVC Biopharma Inc stock is currently trading at $1.13 per share. It touched a 52-week high of $3.13 and a 52-week low of $3.13. Analysts tracking the stock have a 12-month average target price of $2.02.
Its 50-day moving average was $2.78 and 200-day moving average was $5.89 The short ratio stood at 1.4 indicating a short percent outstanding of 0%.
Around 4002.6% of the company’s stock are held by insiders while 184.1% are held by institutions.
Frequently Asked Questions About ABVC Biopharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.